Biomodels' Oral Mucositis Expertise Speeds FDA Approval For ActoGeniX's Phase 1b Trial Of AGO13 In Cancer Patients

Biomodels LLC, a preclinical research organization specializing in cancer support care, announced that its customized research program allowed ActoGeniX NV, a development stage biopharmaceutical company, to rapidly attain Food and Drug Administration (FDA) approval for Phase 1b clinical trials of AGO13 in cancer patients with oral mucositis. Complete news at...

Knocking The Wind Out Of Asthmatics: Help From Hippocrates

Last week the FDA knocked the wind out of asthmatics by requesting the manufacturers of Singulair, a popular leukotriene blocking asthma and allergy drug, to upgrade their warning against psychotic side effects. Further respiratory distress was imposed on Zicam users when the FDA also last week announced warnings that the drug may cause a loss of smell. More at...